# Ivermectin topical solution.
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule.
**SUMMARY:**
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental abbreviated new animal drug application (ANADA) filed by Norbrook Laboratories, Ltd. The supplemental ANADA adds claims for persistent effectiveness against various species of external and internal parasites when cattle are treated with a topical solution of ivermectin.
**DATES:**
This rule is effective February 12, 2007.
**FOR FURTHER INFORMATION CONTACT:**
John K. Harshman, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0169, e-mail: *[email protected]* .
**SUPPLEMENTARY INFORMATION:**
Norbrook Laboratories, Ltd., Station Works, Newry BT35 6JP, Northern Ireland, filed a supplement to ANADA 200-272 for Ivermectin Pour-On for Cattle. The supplemental ANADA adds claims for persistent effectiveness against various species of external and internal parasites that were approved for the pioneer product with 3 years of marketing exclusivity (69 FR 501, January 6, 2004). The supplemental ANADA is approved as of January 19, 2007, and 21 CFR 524.1193 is amended to reflect the approval.
In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
FDA has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to congressional review requirements in 5 U.S.C. 801-808.
**List of Subjects in 21 CFR Part 524**
Animal drugs.
**21 CFR Part 524**
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:
**21 CFR Part 524**
**PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS**
1. The authority citation for 21 CFR part 524 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 524**
2. In § 524.1193, revise the section heading, and paragraphs (b) and (e)(2) to read as follows:
§ 524.1193
(b) *Sponsors* . See Nos. 050604, 051311, 054925, 055529, 058829, 059130, and 066916 in § 510.600(c) of this chapter for use as in paragraph (e) of this section.
(e) * * *
(2) *Indications for use in cattle* . For the treatment and control of: Gastrointestinal roundworms (adults and fourth-stage larvae) *Ostertagia ostertagi* (including inhibited stage), *Haemonchus placei* , *Trichostrongylus axei* , *T. colubriformis* , *Cooperia oncophora* , *C. punctata* , *C. surnabada* , *Oesophagostomum radiatum* ; (adults) *Strongyloides papillosus* , *Trichuris* spp.; lungworms (adults and fourth-stage larvae) *Dictyocaulus viviparus* ; cattle grubs (parasitic stages) *Hypoderma bovis* , *H. lineatum* ; mites *Sarcoptes scabiei* var. *bovis* ; lice *Linognathus vituli* , *Haematopinus eurysternus* , *Damalinia bovis* , *Solenoptes capillatus* ; and horn flies *Haematobia irritans* . It controls infections and prevents reinfection with *O. radiatum* and *D. viviparus* for 28 days after treatment, *C. punctata* and *T. axei* for 21 days after treatment, *H. placei* , *C. oncophora* , and *C. surnabada* for 14 days after treatment, and *D. bovis* for 56 days after treatment.
Dated: February 2, 2007.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.